Study of HIV-1 drug resistance in patients receiving free antiretroviral therapy in China

Virologica Sinica

Volumn 22, Issue 3, 2007, Pages 233-240

  Li, Xin Ping ^a,b,d   Xing, Hui ^b   Wang, Zhe ^b   Si, Xue Feng ^b   Wang, Lian En ^c   Cheng, Hua ^b   Cui, Wei Guo ^b   Jiang, Shu Lin ^b   Liao, Ling Jie ^b   Zhou, Hai Wei ^b   Huang, Jiang Hong ^b   Peng, Hong ^b   Ma, Peng Fei ^b   Shao, Yi Ming ^a,b  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c Queshan Center for Disease Control and Prevention   (China)

^d UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Acquired immunodeficiency syndrome (AIDS); Antiretroviral therapy; Drug resistance; Human Immunodeficiency VirusType 1(HIV 1); Viral load

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CHINA; CONTROLLED STUDY; DRUG RESPONSE; DRUG TREATMENT FAILURE; GENE FREQUENCY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTERNET; INTERVIEW; MUTATIONAL ANALYSIS; PATIENT INFORMATION; SEQUENCE ANALYSIS; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34347250870     PISSN: 10035125     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Alcorn T M, Faruki H. 2000. HIV Resistance Testing: Methods, Utility, and Limitations. Mol Diagn, 5 (3): 159-168.
2. Conway B, Wainberg M A, Hall D, et al. 2001. Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. AIDS, 15 (10): 1269-1274.
3. DeGruttola V, Dix L, D'Aquila R, et al. 2000. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther, 5 (1): 41-48.
4. Finzi D, Hermankova M, Pierson T, et al. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science, 278 (5341): 1295-300.
5. Jiang S L, Wang Z, Xing H, et al. 2005. The laboratory evaluation and analysis of curative effect of anti-HIV treatment in Queshan County of Henan Province. China J AIDS/STD, 11 (12): 81-83. (in Chinese)
6. Johnson A, Brun-Vézinet F, Clotet B, et al. 2005. Update of the Drug Resistance Mutations in HIV-1: 2005. Top HIV Med, 13(1): 51-57.
7. Kantor R, Katzenstein D. 2004. Drug resistance in non-subtype B HIV-1. J Clin Virol, 29: 152-159.
8. Kantor R, Shafer R W, Follansbee S, et al. 2004. Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS, 18 (11): 1503-1511.
9. Li J Y, Li H P, Li L, et al. 2005. Prevalence and evolution of drug resistance HIV-1 variants in Henan, China. Cell Res, 15 (11-12): 843-849.
10. Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS). 2005. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Available at: AIDSinfo web site: http://AIDSinfo.nih.gov.
11. Pereira C F, Paridaen J T. 2004. Anti-HIV drug development - an overview. Curr Pharm Des, 10 (32): 4005-4037.
12. Richman D D, Morton S C, Wrin T, et al. 2004. The prevalence of antiretroviral drug resistance in the United States. AIDS, 18 (10): 1393-1401.
13. Selmi B, Deval J, Alvarez K, et al. 2003. The Y181C substitution in 3′-azido-3′-deoxythymidine-resistant human immunodeficiency virus type 1 reverse transcriptase suppresses the ATP-mediated repair of the 3′-azido-3′-deoxy-thymidine 5′-monophosphate-terminated primer. J Biol Chem, 278 (42): 40464-40472.
14. Shafer R W. 2003. Genotypic Testing for HIV-1 Drug Resistance. Available at Stanford web site: http://hivdb.stanford.edu.
15. Shafer R W, Warford A, Winters M A, et al. 2000. Reproducibility of human immunodeficiency virus type 1 (HIV-1) protease and reverse transcriptase sequencing of plasma samples from heavily treated HIV-1-infected individuals. J Virol Methods, 86 (2): 143-153.
16. Si X F, Huang H L, Wei M, et al. 2004. Prevalence of drug resistance mutations among antiretroviral drug-naive HIV-1-infected patients in China. Chin J Exper Clin Virol, 18 (4): 308-311. (in Chinese).